<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90894">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921751</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG 1201</org_study_id>
    <secondary_id>NCI-2013-01280</secondary_id>
    <secondary_id>RTOG 1201</secondary_id>
    <secondary_id>RTOG-1201</secondary_id>
    <secondary_id>U10CA180868</secondary_id>
    <secondary_id>U10CA021661</secondary_id>
    <nct_id>NCT01921751</nct_id>
  </id_info>
  <brief_title>High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-paclitaxel for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well high or standard intensity radiochemotherapy
      after gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation
      (nab-paclitaxel) work compared with gemcitabine hydrochloride and nab-paclitaxel alone in
      treating patients with pancreatic cancer that cannot be removed by surgery. Drugs used in
      chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, work in different ways
      to stop the growth of tumor cells, either by killing the cells, by stopping them from
      dividing or by stopping them from spreading. Radiation therapy uses high-energy x-rays to
      kill tumor cells. Drugs, such as capecitabine, may make tumor cells more sensitive to
      radiation therapy. Giving radiation therapy in different ways and adding chemotherapy may
      kill more tumor cells. It is not yet known whether high intensity radiochemotherapy after
      gemcitabine hydrochloride and nab-paclitaxel is more effective than standard intensity
      radiochemotherapy after gemcitabine hydrochloride and nab-paclitaxel or gemcitabine
      hydrochloride and nab-paclitaxel alone in treating pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if intensified radiochemotherapy following gemcitabine (gemcitabine
      hydrochloride) and nab-paclitaxel in patients with unresectable pancreatic cancer will show
      a signal for improved 2-year overall survival (OS) from 10% to 22.5% as compared to
      chemotherapy with gemcitabine and nab-paclitaxel alone.

      II. To determine if standard radiochemotherapy, following gemcitabine and nab-paclitaxel, in
      patients with unresectable pancreatic cancer will show a signal for improved 2-year OS from
      10% to 22.5% as compared to chemotherapy with gemcitabine and nab-paclitaxel alone.

      SECONDARY OBJECTIVES:

      I. To evaluate patterns of failure (local and systemic progression) by SMAD family member 4
      (SMAD4) status and intensity of radiation therapy.

      II. To evaluate the impact of radiochemotherapy on OS for the subset of SMAD4 intact
      patients.

      III. To evaluate adverse events associated with the treatments. IV. To evaluate correlation
      between SMAD4 status determined by immunohistochemistry (IHC) and genetic SMAD4 status.

      OUTLINE: Patients are randomized to 1 of 3 treatment arms.

      ARM I: Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes and
      paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8,
      and 15. Treatment repeats every 4 weeks for *3 courses in the absence of disease progression
      or unacceptable toxicity. Beginning 3-5 weeks later, patients undergo high-dose
      intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks (28 fractions) and
      receive concurrent capecitabine orally (PO) twice daily (BID) 5 days a week for 6 weeks.

      ARM II: Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized
      nanoparticle formulation as in Arm I. Beginning 3-5 weeks later, patients undergo
      standard-dose 3-dimensional conformal radiation therapy (3D-CRT) or IMRT 5 days a week for 6
      weeks (28 fractions) and receive capecitabine as in Arm I.

      ARM III: Patients receive gemcitabine hydrochloride IV over 30 minutes and paclitaxel
      albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15.
      Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

      NOTE: *In Arms I and II, 2-6 weeks after completion of radiation therapy, patients resume
      receiving gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle
      formulation until disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 1 month and then every 3
      months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Trial would not be completed in a reasonable timeframe per CTEP guidelines
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
    <description>OS will be estimated by the Kaplan-Meier method. For each comparison of a chemoradiation arm to the chemotherapy alone arm, the distribution of OS estimated between the two arms will be compared using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with OS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS within SMAD 4 subsets</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of failure (local and metastatic failure)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Local and distant failure will be estimated by the cumulative incidence method and the comparison of these endpoints between treatment arms will be done using Gray's test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SMAD 4 status</measure>
    <time_frame>Baseline</time_frame>
    <description>The correlation between SMAD4 status determined by IHC and genetic SMAD4 status will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (gemcitabine, nab-paclitaxel, high-dose IMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for *3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-5 weeks later, patients undergo high-dose IMRT 5 days a week for 6 weeks (28 fractions) and receive concurrent capecitabine PO BID 5 days a week for 6 weeks.
NOTE: *2-6 weeks after completion of radiation therapy, patients resume receiving gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (gemcitabine, nab-paclitaxel, standard-dose 3D-CRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation as in Arm I. Beginning 3-5 weeks later, patients undergo standard-dose 3D-CRT or IMRT 5 days a week for 6 weeks (28 fractions) and receive capecitabine as in Arm I.
NOTE: *2-6 weeks after completion of radiation therapy, patients resume receiving gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (gemcitabine, nab-paclitaxel)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Conformal Radiation Therapy</intervention_name>
    <description>Undergo 3D-CRT</description>
    <arm_group_label>Arm II (gemcitabine, nab-paclitaxel, standard-dose 3D-CRT)</arm_group_label>
    <other_name>3-dimensional radiation therapy</other_name>
    <other_name>3D-CRT</other_name>
    <other_name>Conformal Therapy</other_name>
    <other_name>Radiation Conformal Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (gemcitabine, nab-paclitaxel, high-dose IMRT)</arm_group_label>
    <arm_group_label>Arm II (gemcitabine, nab-paclitaxel, standard-dose 3D-CRT)</arm_group_label>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (gemcitabine, nab-paclitaxel, high-dose IMRT)</arm_group_label>
    <arm_group_label>Arm II (gemcitabine, nab-paclitaxel, standard-dose 3D-CRT)</arm_group_label>
    <arm_group_label>Arm III (gemcitabine, nab-paclitaxel)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Arm I (gemcitabine, nab-paclitaxel, high-dose IMRT)</arm_group_label>
    <arm_group_label>Arm II (gemcitabine, nab-paclitaxel, standard-dose 3D-CRT)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (gemcitabine, nab-paclitaxel, high-dose IMRT)</arm_group_label>
    <arm_group_label>Arm II (gemcitabine, nab-paclitaxel, standard-dose 3D-CRT)</arm_group_label>
    <arm_group_label>Arm III (gemcitabine, nab-paclitaxel)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel Albumin-Stabilized Nanoparticle Formulation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (gemcitabine, nab-paclitaxel, high-dose IMRT)</arm_group_label>
    <arm_group_label>Arm II (gemcitabine, nab-paclitaxel, standard-dose 3D-CRT)</arm_group_label>
    <arm_group_label>Arm III (gemcitabine, nab-paclitaxel)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>ABI-007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Albumin-bound Paclitaxel</other_name>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>nab-paclitaxel</other_name>
    <other_name>Nanoparticle Albumin-bound Paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel</other_name>
    <other_name>protein-bound paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of adenocarcinoma of the pancreas
             prior to registration

          -  Tumor diameter =&lt; 7 cm

          -  Unresectable by radiographic criteria (pancreas protocol computed tomography [CT] or
             magnetic resonance imaging [MRI]) or exploration within 30 days prior to registration

          -  A cell block or core biopsy must be submitted for central review and analysis of
             SMAD4 status as soon as possible following step 1 registration

          -  No distant metastases, based upon the following minimum diagnostic workup:

               -  History/physical examination within 30 days prior to registration

               -  Whole body fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/CT
                  within 30 days prior to registration

                    -  NOTE: if whole-body FDG-PET/CT is not performed, CT of the chest and CT (or
                       MRI) of abdomen and pelvis must be obtained (imaging of abdomen and pelvis
                       need not be repeated if already included in pancreas protocol study)

          -  Zubrod performance status 0-1 within 30 days prior to registration

          -  Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm^3

          -  Platelets &gt;= 100,000 cells/mm^3

          -  Hemoglobin &gt;= 8.0 g/dl (NOTE: the use of transfusion or other intervention to achieve
             hemoglobin [Hgb] &gt;= 8.0 g/dl is acceptable)

          -  Cancer antigen 19-9 (CA19-9); NOTE: in the event that a stent has been placed and
             biliary obstruction has been relieved, the CA19-9 should be drawn post stent
             placement

          -  Creatinine &lt; 2 mg/dl; glomerular filtration rate (GFR) &gt; 50 mL/min (Cockroft and
             Gault formula)

          -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x ULN

          -  Activated partial thromboplastin time (aPTT) =&lt; 1.2 x ULN

          -  Prothrombin time (PT) =&lt; 1.2 x ULN

          -  Patient must provide study specific informed consent prior to study entry

          -  Women of childbearing potential and male participants must practice adequate
             contraception during protocol treatment and for at least 6 months following treatment

          -  For females of child-bearing potential, negative serum pregnancy test within 30 days
             prior to registration

        Exclusion Criteria:

          -  More than one primary lesion

          -  Prior invasive malignancy (unless disease free for a minimum of 1095 days [3 years]);
             non-melanomatous skin cancer and previous early prostate cancer that had a non-rising
             prostate-specific antigen (PSA) are eligible

          -  Prior systemic anti-cancer therapy for pancreatic cancer; note that prior
             chemotherapy for a different cancer is allowable

          -  Prior radiation therapy to the abdomen that would result in overlap of radiation
             therapy fields

          -  Severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration

               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 days before
                  registration

               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;
                  note, however, that laboratory tests for liver function and coagulation
                  parameters are not required for entry into this protocol

               -  Acquired immune deficiency syndrome (AIDS) based upon current Centers for
                  Disease Control (CDC) definition; note, however, that human immunodeficiency
                  virus (HIV) testing is not required for entry into this protocol;
                  protocol-specific requirements may also exclude immuno-compromised patients

          -  Pregnancy or women of childbearing potential, women who cannot discontinue
             breastfeeding and men who are sexually active and not willing/able to use medically
             acceptable forms of contraception

          -  Prior allergic reaction to the study drug(s) involved in this protocol

          -  Pre-existing grade 2 or greater neuropathy

          -  Distant metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar Ben-Josef</last_name>
    <role>Principal Investigator</role>
    <affiliation>NRG Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland-Broadway</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Cancer Treatment Center</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615-7827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiation Oncology Associates PC</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkview Hospital Randallia</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-William R Bliss Cancer Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic North-Bemidgi</name>
      <address>
        <city>Bemidji</city>
        <state>Minnesota</state>
        <zip>56601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rice Memorial Hospital</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CoxHealth South Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Health Medical Center-Hopewell</name>
      <address>
        <city>Pennington</city>
        <state>New Jersey</state>
        <zip>08534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Bismarck Medical Center</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Maris Cancer Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paoli Memorial Hospital</name>
      <address>
        <city>Paoli</city>
        <state>Pennsylvania</state>
        <zip>19301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay-Dee Hospital Center</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Vermont Medical Center/National Life Cancer Treatment</name>
      <address>
        <city>Berlin</city>
        <state>Vermont</state>
        <zip>05602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Medical Center</name>
      <address>
        <city>Marinette</city>
        <state>Wisconsin</state>
        <zip>54143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Door County Cancer Center</name>
      <address>
        <city>Sturgeon Bay</city>
        <state>Wisconsin</state>
        <zip>54235-1495</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 1, 2016</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SMAD4</keyword>
  <keyword>IMRT</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>high-dose radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
